Theophylline improves steroid sensitivity in acute alcoholic hepatitis

Hepatology

Volumn 52, Issue 1, 2010, Pages 126-131

  Kendrick, Stuart F W ^a   Henderson, Elsbeth ^a   Palmer, Jeremy ^a   Jones, David E J ^a   Day, Chris P ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BILIRUBIN; CORTICOSTEROID; CREATININE; DEXAMETHASONE; MARKER; PHYTOHEMAGGLUTININ; PREDNISOLONE; PROTHROMBIN; THEOPHYLLINE; THYMIDINE; TRITIUM;

ADULT; AGE DISTRIBUTION; ALCOHOL LIVER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CONVALESCENCE; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; DISEASE SEVERITY; DNA SYNTHESIS; DRUG RESPONSE; DRUG WITHDRAWAL; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MALE; PRESCRIPTION; PRIORITY JOURNAL; PROTHROMBIN TIME; SURVIVOR; TREATMENT RESPONSE;

ACUTE DISEASE; ADRENAL CORTEX HORMONES; ADULT; DEXAMETHASONE; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS, ALCOHOLIC; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; SPAIN; THEOPHYLLINE; TREATMENT OUTCOME;

EID: 77954224400     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.23666     Document Type: Article

References (23)

1. Mathurin P, Mendenhall CL, Carithers RL, Ramond M-J, Maddrey WC, Garstide P, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol 2002;36:480-487.
2. Baptista A. Alcoholic liver disease: morphological manifestations. Review by an international group. Lancet 1981;1:707-711.
3. Bird G, Sheron N, Goka A, Alexander G, Williams R. Increased plasma tumor necrosis factor in severe alcoholic hepatitis. Ann Intern Med 1990;112:917-920.
4. Sheron N, Bird G, Goka J, Alexander G, Williams R. Elevated plasma interleukin-6 and increased severity and mortality in alcoholic hepatitis. Clin Exp Immunol 1991;84:449-453.
5. Sheron N, Bird G, Koskinas J, Portmann B, Ceska M, Lindley I, et al. Circulating and tissue levels of the neutrophil chemotaxin interleukin-8 are elevated in severe acute alcoholic hepatitis, and tissue levels correlate with neutrophil infiltration. HEPATOLOGY 1993;18:41-46.
6. Mathurin P, Abdelnour M, Ramond M-J, Carbonell N, Fartoux L, Serfaty L, et al. Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone. HEPATOLOGY 2003;38:1363-1369.
7. Hearing SD, Norman M, Probert CSJ, Haslam N, Dayan CM. Predicting therapeutic outcome in severe ulcerative colitis by measuring in vitro steroid sensitivity of proliferating peripheral blood lymphocytes. Gut 1999;45:382-388. (Pubitemid 29400714)
8. Barnes PJ, Ito K, Adcock IM. Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet 2004;363:731-733. (Pubitemid 38296564)
9. Barnes PJ. Theophylline in chronic obstructive pulmonary disease: new horizons. Proc Am Thorac Soc 2005;2:334-339. (Pubitemid 41699692)
10. Carithers RJ, Herlong H, Diehl A, Shaw E, Combes B, Fallon H, et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis: a randomized multicenter trial. Ann Intern Med 1989;110:685-690. (Pubitemid 19121221)
11. Christensen E, Schlichting P, Fauerholdt L, Gluud C, Andersen PK, Juhl E, et al. Prognostic value of Child-Turcotte criteria in medically treated cirrhosis. HEPATOLOGY 1984;4:430-435. (Pubitemid 14116643)
12. Dunn W, Jamil LH, Brown LS, Wiesner RH, Kim WR, Menon KVN, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. HEPATOLOGY 2005;41:353-358. (Pubitemid 40165379)
13. Forrest EH, Evans CDJ, Stewart S, Phillips M, Oo YH, McAvoy NC, et al. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut 2005;54:1174-1179.
14. Corrigan CJ, Brown PH, Barnes NC, Szefler SJ, Tsai JJ, Frew AJ, et al. Glucocorticoid resistance in chronic asthma: glucocorticoid pharmacokinetics, glucocorticoid receptor characteristics, and inhibition of peripheral blood T cell proliferation by glucocorticoids in vitro. Am Rev Respir Dis 1991;144:1016-1025.
15. Kirkham BW, Corkill MM, Davison SC, Panayi GS. Response to glucocorticoid treatment in rheumatoid arthritis: in vitro cell mediated immune assay predicts in vivo responses. J Rheumatol 1991;18:821-825.
16. Langhoff E, Ladefoged J, Jakobsen BK, Platz P, Ryder LP, Svejgaard A, et al. Recipient lymphocyte sensitivity to methylprednisolone affects cadaver kidney graft survival. Lancet 1986;1:1296-1297. (Pubitemid 16114049)
17. Stewart SF, Vidali M, Day CP, Albano E, Jones DEJ. Oxidative stress as a trigger for cellular immune responses in patients with alcoholic liver disease. HEPATOLOGY 2004;39:197-203. (Pubitemid 38461482)
18. Hearing SD, Norman M, Smyth C, Foy C, Dayan CM. Wide variation in lymphocyte steroid sensitivity among healthy human volunteers. J Clin Endocrinol Metab 1999;84:4149-4154.
19. Kendrick SFW, O'Boyle G, Mann J, Zeybel M, Palmer J, Jones D, et al. Acetate, the key modulator of inflammatory responses in acute alcoholic hepatitis. HEPATOLOGY 2010; doi: 10.1002/hep.23572.
20. Gobejishvili L, Barve S, Joshi-Barve S, McClain C. Enhanced PDE4B expression augments LPS-inducible TNF expression in ethanol-primed monocytes: relevance to alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol 2008;295:G718-G724.
21. Klatsky AL, Morton C, Udaltsova N, Friedman GD. Coffee, cirrhosis, and transaminase enzymes. Arch Intern Med 2006;166:1190-1195.
22. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119:1637-1648.
23. Louvet A, Diaz E, Dharancy S, Coevoet H, Texier F, Thevenot T, et al. Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids. J Hepatol 2008;48:465-470.